Skandinaviska Enskilda Banken (SEB)’s Iovance Biotherapeutics IOVA Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-155,684	Closed	-$518K	–	865
2025 Q1	$518K	Hold	155,684	–	–	﹤0.01%	686
2024 Q4	$1.11M	Buy	155,684 +41,732	+37%	+$387K	0.01%	647
2024 Q3	$1.07M	Hold	113,952	–	–	﹤0.01%	662
2024 Q2	$912K	Hold	113,952	–	–	﹤0.01%	649
2024 Q1	$1.69M	Buy	113,952 +17,334	+18%	+$202K	0.01%	606
2023 Q4	$785K	Hold	96,618	–	–	﹤0.01%	725
2023 Q3	$440K	Hold	96,618	–	–	﹤0.01%	778
2023 Q2	$680K	Hold	96,618	–	–	﹤0.01%	752
2023 Q1	$590K	Sell	96,618 -4,756	-5%	-$32.8K	﹤0.01%	756
2022 Q4	$648K	Sell	101,374 -5,875	-5%	-$45.9K	﹤0.01%	710
2022 Q3	$1.03M	Buy	107,249 +60,039	+127%	+$692K	0.01%	676
2022 Q2	$521K	Hold	47,210	–	–	﹤0.01%	801
2022 Q1	$786K	Hold	47,210	–	–	﹤0.01%	784
2021 Q4	$917K	Hold	47,210	–	–	﹤0.01%	781
2021 Q3	$1.16M	Buy	47,210 +24,544	+108%	+$578K	0.01%	762
2021 Q2	$590K	Hold	22,666	–	–	﹤0.01%	863
2021 Q1	$718K	Buy	+22,666	New	+$940K	﹤0.01%	881

Other funds holding IOVA

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s IOVA Position: Q2 2025 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 155,684 shares — an estimated $518K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in IOVA in Q1 2021 and held it in 17 quarters. The position peaked at $1.69M in Q1 2024. 254 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

Skandinaviska Enskilda Banken (SEB) reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 155,684 Iovance Biotherapeutics shares in Q2 2025, an estimated $518K.
Skandinaviska Enskilda Banken (SEB) first reported a position in Iovance Biotherapeutics in Q1 2021 and held it in 17 quarters.
Skandinaviska Enskilda Banken (SEB)'s Iovance Biotherapeutics position peaked at $1.69M in Q1 2024.
254 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q2 2025, filed 13 Aug 2025.